Project Grant R21AI180460
Award Date
8/21/24
Completion Date
7/31/26
Dollars Obligated
$529K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $483,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital. The grant, with a project period from March 2025 to February 2030, aims to define the protective CD4+ T cell response that supports effective CD8+ T cell immunity against the Hepatitis C Virus (HCV). The research will leverage historical blood and liver samples...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,175 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Children's Mercy Hospital in Kansas City, Missouri. The grant supports the development of a mosaic enterovirus mRNA vaccine to prevent hand, foot and mouth disease (HFMD). Specifically, the project aims to engineer a multivalent mosaic HEV-A mRNA-encoded virus-like particle (VLP) vaccine and isolate broadly...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $682,879 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical College of Wisconsin, Inc. to conduct research on the impact of human cytomegalovirus (HCMV) infection on the development of human neural tissues. The 5-year project aims to: 1) define the transcriptional and cellular disruptions to developing human neural cells caused by HCMV infection, 2) determine the...
The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the development of monoclonal antibody (mAb) treatments for paramyxovirus infections. The key objectives are to: 1) Define the human B cell repertoire and neutralizing mAbs targeting the parainfluenza virus (PIV) fusion and hemagglutinin-neuraminidase surface proteins; 2) Determine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
This Project Grant award, totaling $744,977.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at Emory University to explore the role of T cells in providing protection against respiratory virus transmission. Key objectives include defining the cellular interactions and molecular mechanisms of tissue-resident memory T cells (TRM) that can limit the spread of...